The Role of BCNU Polymer Wafers (Gliadel) in the Treatment of Malignant Glioma

Neurosurgery Clinics of North America

Volumn 23, Issue 2, 2012, Pages 289-295

  Nagpal, Seema ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

BCNU wafers; Gliadel; Glioma; Local chemotherapy

Indexed keywords

6 O BENZYLGUANINE; BEVACIZUMAB; CARBOPLATIN; CARMUSTINE; IRINOTECAN; LOMUSTINE; PLACEBO; POLIFEPROSAN; PROCARBAZINE; SEBACIC ACID; TEMOZOLOMIDE; VINCRISTINE;

BRAIN EDEMA; CANCER SURVIVAL; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG POTENTIATION; DRUG RELEASE; DRUG RESPONSE; DRUG SAFETY; GLIOMA; HUMAN; INTRACRANIAL HYPERTENSION; LIQUORRHEA; NEUROLOGIC DISEASE; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SEIZURE; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CARMUSTINE; DECANOIC ACIDS; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; GLIOMA; HUMANS; POLYESTERS; TREATMENT OUTCOME;

EID: 84858609055     PISSN: 10423680     EISSN: 15581349     Source Type: Journal    
DOI: 10.1016/j.nec.2012.01.004     Document Type: Review

References (45)

1. Owens G., Javid R., Tallon M., et al. Arterial infusion chemotherapy of primary gliomas. JAMA 1963, 186:802-803.
2. Garfield J., Dayan A.D. Postoperative intracavitary chemotherapy of malignant gliomas. A preliminary study using methotrexate. J Neurosurg 1973, 39(3):315-322.
3. Heppner F., Diemath H.E. Acta Neurochir (Wien) 1963, 11:287-293. [in German].
4. Wilkinson H.A., Kornblith P., Weems S. Focal chemotherapy of brain tumours using semipermeable membranes. J Neurol Neurosurg Psychiatry 1977, 40(4):389-394.
5. Wilson C.B., Gutin P., Boldrey E.B., et al. Single-agent chemotherapy of brain tumors. A five-year review. Arch Neurol 1976, 33(11):739-744.
6. Fewer D., Wilson C.B., Boldrey E.B., et al. The chemotherapy of brain tumors. Clinical experience with carmustine (BCNU) and vincristine. JAMA 1972, 222(5):549-552.
7. Johnson D.W., Parkinson D., Wolpert S.M., et al. Intracarotid chemotherapy with 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU) in 5% dextrose in water in the treatment of malignant glioma. Neurosurgery 1987, 20(4):577-583.
8. Langer R., Folkman J. Polymers for the sustained release of proteins and other macromolecules. Nature 1976, 263(5580):797-800.
9. Wang P.P., Frazier J., Brem H. Local drug delivery to the brain. Adv Drug Deliv Rev 2002, 54(7):987-1013.
10. Tamargo R.J., Myseros J.S., Epstein J.I., et al. Interstitial chemotherapy of the 9L gliosarcoma: controlled release polymers for drug delivery in the brain. Cancer Res 1993, 53(2):329-333.
11. Fleming A.B., Saltzman W.M. Pharmacokinetics of the carmustine implant. Clin Pharmacokinet 2002, 41(6):403-419.
12. Grossman S.A., Reinhard C., Colvin O.M., et al. The intracerebral distribution of BCNU delivered by surgically implanted biodegradable polymers. J Neurosurg 1992, 76(4):640-647.
13. Fung L.K., Ewend M.G., Sills A., et al. Pharmacokinetics of interstitial delivery of carmustine, 4-hydroperoxycyclophosphamide, and paclitaxel from a biodegradable polymer implant in the monkey brain. Cancer Res 1998, 58(4):672-684.
14. Gu B., DeAngelis L.M. Enhanced cytotoxicity of bioreductive antitumor agents with dimethyl fumarate in human glioblastoma cells. Anticancer Drugs 2005, 16(2):167-174.
15. Hunter K.J., Deen D.F., Pellarin M., et al. Effect of alpha-difluoromethylornithine on 1,3-bis(2-chloroethyl)-1-nitrosourea and cis-diamminedichloroplatinum(II) cytotoxicity, DNA interstrand cross-linking, and growth in human brain tumor cell lines in vitro. Cancer Res 1990, 50(9):2769-2772.
16. Brem H., Tamargo R.J., Olivi A., et al. Biodegradable polymers for controlled delivery of chemotherapy with and without radiation therapy in the monkey brain. J Neurosurg 1994, 80(2):283-290.
17. Brem H., Mahaley M.S., Vick N.A., et al. Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. J Neurosurg 1991, 74(3):441-446.
18. Brem H., Ewend M.G., Piantadosi S., et al. The safety of interstitial chemotherapy with BCNU-loaded polymer followed by radiation therapy in the treatment of newly diagnosed malignant gliomas: phase I trial. J Neurooncol 1995, 26(2):111-123.
19. Brem H., Piantadosi S., Burger P.C., et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-Brain Tumor Treatment Group. Lancet 1995, 345(8956):1008-1012.
20. Westphal M., Hilt D.C., Bortey E., et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol 2003, 5(2):79-88.
21. Westphal M., Ram Z., Riddle V., et al. Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial. Acta Neurochir (Wien) 2006, 148(3):269-275. [discussion: 75].
22. Valtonen S., Timonen U., Toivanen P., et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study. Neurosurgery 1997, 41(1):44-48. [discussion: 48-9].
23. Olivi A., Grossman S.A., Tatter S., et al. Dose escalation of carmustine in surgically implanted polymers in patients with recurrent malignant glioma: a new approaches to brain tumor therapy CNS consortium trial. J Clin Oncol 2003, 21(9):1845-1849.
24. Whittle I.R., Lyles S., Walker M. Gliadel therapy given for first resection of malignant glioma: a single centre study of the potential use of Gliadel. Br J Neurosurg 2003, 17(4):352-354.
25. Stewart L.A. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 2002, 359(9311):1011-1018.
26. Noel G., Schott R., Froelich S., et al. Retrospective comparison of chemoradiotherapy followed by adjuvant chemotherapy, with or without prior Gliadel implantation (carmustine) after initial surgery in patients with newly diagnosed high-grade gliomas. Int J Radiat Oncol Biol Phys 2012, 82(2):749-755.
27. Attenello F.J., Mukherjee D., Datoo G., et al. Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience. Ann Surg Oncol 2008, 15(10):2887-2893.
28. Menei P., Metellus P., Parot-Schinkel E., et al. Biodegradable carmustine wafers (Gliadel) alone or in combination with chemoradiotherapy: the French experience. Ann Surg Oncol 2010, 17(7):1740-1746.
29. Dorner L., Ulmer S., Rohr A., et al. Space-occupying cyst development in the resection cavity of malignant gliomas following Gliadel(R) implantation-incidence, therapeutic strategies, and outcome. J Clin Neurosci 2011, 18(3):347-351.
30. Subach B.R., Witham T.F., Kondziolka D., et al. Morbidity and survival after 1,3-bis(2-chloroethyl)-1-nitrosourea wafer implantation for recurrent glioblastoma: a retrospective case-matched cohort series. Neurosurgery 1999, 45(1):17-22. [discussion: 22-3].
31. McGovern P.C., Lautenbach E., Brennan P.J., et al. Risk factors for postcraniotomy surgical site infection after 1,3-bis(2-chloroethyl)-1-nitrosourea (Gliadel) wafer placement. Clin Infect Dis 2003, 36(6):759-765.
32. Weber E.L., Goebel E.A. Cerebral edema associated with Gliadel wafers: two case studies. Neuro Oncol 2005, 7(1):84-89.
33. Giese A., Kucinski T., Knopp U., et al. Pattern of recurrence following local chemotherapy with biodegradable carmustine (BCNU) implants in patients with glioblastoma. J Neurooncol 2004, 66(3):351-360.
34. Weingart J., Grossman S.A., Carson K.A., et al. Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial. J Clin Oncol 2007, 25(4):399-404.
35. Quinn J.A., Jiang S.X., Carter J., et al. Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme. Clin Cancer Res 2009, 15(3):1064-1068.
36. Gururangan S., Cokgor L., Rich J.N., et al. Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas. Neuro Oncol 2001, 3(4):246-250.
37. Limentani S.A., Asher A., Heafner M., et al. A phase I trial of surgery, Gliadel wafer implantation, and immediate postoperative carboplatin in combination with radiation therapy for primary anaplastic astrocytoma or glioblastoma multiforme. J Neurooncol 2005, 72(3):241-244.
38. Sampath P, Sungarian A, Alderson L, et al. BCNU-impregnated wafers (Gliadel) plus irinotecan (Camptosar) in combination treatment for patients with recurrent glioblastoma multiforme [abstract]. Congress of Neurological Surgeons, Boston, October 8-13, 2005.
39. Smith K.A., Ashby L.S., Gonzalez L.F., et al. Prospective trial of gross-total resection with Gliadel wafers followed by early postoperative Gamma Knife radiosurgery and conformal fractionated radiotherapy as the initial treatment for patients with radiographically suspected, newly diagnosed glioblastoma multiforme. J Neurosurg 2008, 109(Suppl):106-117.
40. Affronti M.L., Heery C.R., Herndon J.E., et al. Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy. Cancer 2009, 115(15):3501-3511.
41. McGirt M.J., Than K.D., Weingart J.D., et al. Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. J Neurosurg 2009, 110(3):583-588.
42. Bock H.C., Puchner M.J., Lohmann F., et al. First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience. Neurosurg Rev 2010, 33(4):441-449.
43. Salvati M., D'Elia A., Frati A., et al. Safety and feasibility of the adjunct of local chemotherapy with biodegradable carmustine (BCNU) wafers to the standard multimodal approach to high grade gliomas at first diagnosis. J Neurosurg Sci 2011, 55(1):1-6.
44. Hassenbusch S.J., Nardone E.M., Levin V.A., et al. Stereotactic injection of DTI-015 into recurrent malignant gliomas: phase I/II trial. Neoplasia 2003, 5(1):9-16.
45. Jenkinson M.D., Smith T.S., Haylock B., et al. Phase II trial of intratumoral BCNU injection and radiotherapy on untreated adult malignant glioma. J Neurooncol 2010, 99(1):103-113.